Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increased use of key agents such as Pfizer's Lyrica, Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar/Ariclaim and Forest Laboratories/Cypress Bioscience's Savella will drive eight percent annual growth in the fibromyalgia market through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Fibromyalgia also finds that improved diagnosis of the disorder and an expanding drug-treated population will be major market drivers over the next decade, particularly in the U.S. where the greatest growth in diagnosis rates is expected to occur. In the world's major markets, the U.S. accounted for nearly 80 percent of fibromyalgia drug sales in 2008 and will continue to account for more than two-thirds of fibromyalgia drug sales through 2018. Expansion of the market in Europe and Japan will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

"Uptake of Lyrica and Cymbalta/Xeristar/Ariclaim will be limited in Europe because both agents received a negative opinion from European regulatory authorities for approval for fibromyalgia," said Decision Resources Analyst Andrea Buurma, B.A. "Although the decision for Savella has not been made yet, regulators' initial refusal to recommend Lyrica's and Cymbalta's marketing authorizations for fibromyalgia indicates more rigorous standards in this region -- it is not clear whether Savella will be able to meet these standards."

The report also finds that, owing to its status as the first-ever approved agent for fibromyalgia and its favorable safety and tolerability profile, Lyrica will remain the dominant U.S. patient and market share leader through 2018 for fibromyalgia treatment. In the U.S., nearly half of the drug-treated fibromyalgia population received Lyrica in 2008, and this patient share will not change through 2018.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Fibromyalgia: Assessing Current and Future Opportunities in an Expanding Drug-Treated Population. This webinar will be held on Tuesday, July 28 at 2 p.m. EDT. For more information, please contact Gisselle Morales at 781-296-2691 or email her at gmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources               Decision Resources, Inc.   Christopher Comfort              Elizabeth Marshall   781-296-2597                     781-296-2563   ccomfort@dresources.com          emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials

View Now